NASDAQ:PCSA Processa Pharmaceuticals - PCSA News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.90 +0.05 (+5.88%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.85▼$0.9450-Day Range$0.86▼$2.0452-Week Range$0.80▼$4.52Volume25,551 shsAverage Volume44,546 shsMarket Capitalization$14.39 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address PCSA Media Mentions By Week PCSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCSA News Sentiment▼0.000.69▲Average Medical News Sentiment PCSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCSA Articles This Week▼00▲PCSA Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineProcessa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.finance.yahoo.com - January 4 at 10:18 AMProcessa Pharmaceuticals Stock Climbs on Latest Data from Gastroparesis Studymarketwatch.com - December 15 at 3:27 PMProcessa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptomsfinance.yahoo.com - December 14 at 3:52 PMProcessa jumps 11% after mid-stage data for gastroparesis candidatemsn.com - December 14 at 10:52 AMProcessa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trialfinance.yahoo.com - December 14 at 10:52 AMProcessa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 13 at 1:40 AMProcessa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - November 8 at 6:22 PMPCS12852 Improves Gastric Emptying in Gastroparesis Patientsfinance.yahoo.com - November 8 at 1:21 PMEarnings Preview: Processa Pharmaceuticalsmsn.com - November 7 at 8:15 PMProcessa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. ESTfinance.yahoo.com - November 2 at 5:50 PMProcessa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trialfinance.yahoo.com - November 1 at 5:24 PMProcessa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programsfinance.yahoo.com - September 15 at 8:44 AMProcessa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022finance.yahoo.com - September 7 at 10:58 AMProcessa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Boardfinance.yahoo.com - August 16 at 11:51 AMProcessa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 14 at 9:34 AMProcessa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 12 at 12:20 PMInvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Callmarketwatch.com - August 10 at 10:42 AMProcessa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. ESTfinance.yahoo.com - August 5 at 6:09 PMProcessa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499finance.yahoo.com - August 4 at 11:23 AMProcessa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499finance.yahoo.com - August 3 at 8:47 PMProcessa Pharmaceuticals Rings the Closing Bellnasdaq.com - July 12 at 11:47 PMProcessa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022finance.yahoo.com - July 12 at 8:54 AMHere's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situationfinance.yahoo.com - June 24 at 9:36 AMPCSA Processa Pharmaceuticals, Inc.seekingalpha.com - June 18 at 10:26 PMBuying Power of Bitcoin vs. Processa Pharmaceuticals at New 52-Week Highnasdaq.com - May 16 at 1:16 PMProcessa Pharmaceuticals Non-GAAP EPS of -$0.20seekingalpha.com - May 14 at 6:57 PMProcessa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 14 at 6:57 PMProcessa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 13 at 1:26 AMProcessa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. ESTfinance.yahoo.com - May 5 at 11:10 AMProcessa begins dosing in phase 1b trial of chemotherapy combo for gastrointestinal cancerseekingalpha.com - April 20 at 3:16 PMProcessa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)finance.yahoo.com - April 20 at 10:13 AMProcessa Pharmaceuticals Announces First Patient Enrolled In PCS12852 Phase 2a Trial For The Treatment Of Gastroparesisbenzinga.com - April 5 at 10:56 AMProcessa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesisfinance.yahoo.com - April 5 at 10:56 AMProcessa Pharmaceuticals GAAP EPS of -$0.75 misses by $0.01seekingalpha.com - March 30 at 6:39 PMProcessa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. ESTfinance.yahoo.com - March 23 at 12:39 PMProcessa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conferencefinance.yahoo.com - March 10 at 9:09 AMA number of insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock last year, which is great news for shareholdersnasdaq.com - February 1 at 1:36 PMProcessa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022finance.yahoo.com - January 26 at 10:19 AMMultiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholdersfinance.yahoo.com - January 17 at 5:06 PMProcessa Pharmaceuticals, Inc. Common Stock (PCSA)nasdaq.com - January 13 at 7:40 PMProcessa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Updatefinance.yahoo.com - November 11 at 7:48 PMWhat You Need To Know About Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Investor Compositionnasdaq.com - November 2 at 1:59 AMProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. ESTfinance.yahoo.com - October 26 at 9:02 AMWhat Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares?finance.yahoo.com - October 19 at 2:15 PMProcessa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesisfinance.yahoo.com - October 12 at 9:30 AMProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences - Updatesg.finance.yahoo.com - September 16 at 11:10 AMProcessa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plansnasdaq.com - September 1 at 6:03 PMCompanies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growthfinance.yahoo.com - August 20 at 6:02 PMProcessa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Updatefinance.yahoo.com - August 12 at 8:38 PMOcuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Updateca.finance.yahoo.com - August 12 at 10:37 AM Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:PCSA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.